Half of the global overweight/obese adult population have metabolic-dysfunction-associated fatty liver disease (MAFLD), with prevalence rising, even among non-obese individuals. This increase is observed globally and mostly in low- and low-middleincome countries of Africa, Asia and South America and represents a great worldwide burden on healthcare expenditures. Lifestyle changes and a healthy diet are still th...
Background & aims: Non-alcoholic fatty liver disease (NAFLD) is a highly prevalent, yet largely underappreciated liver condition which is closely associated with obesity and metabolic disease. Despite affecting an estimated 1 in 4 adults globally, NAFLD is largely absent on national and global health agendas. Methods: We collected data from 102 countries, accounting for 86% of the world population, on NAFLD pol...
Non- alcoholic fatty liver disease (NAFLD) is now the leading cause of chronic liver disease globally. Despite the increased demand placed on health- care systems, little attention has been given to the design and implementation of efficient and effective models of care for patients with NAFLD. In many health- care settings, no formal pathways exist and, where pathways are in place, they are often not standardi...
Non-alcoholic fatty liver disease (NAFLD) is a potentially serious liver disease that affects approximately one-quarter of the global adult population, causing a substantial burden of ill health with wide-ranging social and economic implications. It is a multisystem disease and is considered the hepatic component of metabolic syndrome. Unlike other highly prevalent conditions, NAFLD has received little attentio...